Filtered By:
Source: Vaccine

This page shows you your search results in order of date.

Order by Relevance | Date

Total 21 results found since Jan 2013.

Association of pneumococcal vaccination with cardiovascular diseases in older adults: The vaccine effectiveness, networking, and universal safety (VENUS) study
This study aimed to investigate the protective effect of PPSV23 on cardiovascular events in adults aged ≥ 65 years. This population-based nested case-control study was conducted using the claims data and vaccine records between April 2015 and March 2020 from the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) Study. PPSV23 vaccination was identified using vaccination records in each municipality. The primary outcome was acute myocardial infarction (AMI) or stroke. The adjusted odds ratios (aORs) with 95% confidence intervals (CIs) for PPSV23 vaccination were calculated using conditional logistic regressio...
Source: Vaccine - March 4, 2023 Category: Allergy & Immunology Authors: Nobuhiro Narii Tetsuhisa Kitamura Sho Komukai Ling Zha Masayo Komatsu Fumiko Murata Megumi Maeda Kosuke Kiyohara Tomotaka Sobue Haruhisa Fukuda Source Type: research

Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020
CONCLUSION: AESI background rates varied by database and demographics and fluctuated in March-December 2020, but most returned to pre-pandemic levels after May 2020. It is critical to standardize demographics and consider seasonal and other trends when comparing historical rates with post-vaccination AESI rates in the same database to evaluate COVID-19 vaccine safety.PMID:36404170 | DOI:10.1016/j.vaccine.2022.11.003
Source: Vaccine - November 20, 2022 Category: Allergy & Immunology Authors: Keran Moll Bradley Lufkin Kathryn R Fingar Cindy Ke Zhou Ellen Tworkoski Chianti Shi Shayan Hobbi Mao Hu Minya Sheng Jillian McCarty Shanlai Shangguan Timothy Burrell Yoganand Chillarige Jeff Beers Patrick Saunders-Hastings Stella Muthuri Kathryn Edwards Source Type: research

A post-marketing safety assessment of COVID-19 mRNA vaccination for serious adverse outcomes using administrative claims data linked with vaccination registry in a city of Japan
CONCLUSION: The findings suggested that the COVID-19 mRNA vaccine was generally safe, whilst a signal of pulmonary embolism following the first dose of the COVID-19 mRNA vaccine was observed.PMID:36371366 | DOI:10.1016/j.vaccine.2022.10.088
Source: Vaccine - November 12, 2022 Category: Allergy & Immunology Authors: Yoshinori Takeuchi Masao Iwagami Sachiko Ono Nobuaki Michihata Kohei Uemura Hideo Yasunaga Source Type: research

Predictors of herpes zoster vaccination among Australian adults aged 65 and over
CONCLUSION(S): Further research is required to understand the barriers to HZ vaccine uptake. Increasing the funding eligibility for those who are at risk of complications from shingles, or lowering the age of eligibility, may increase vaccine coverage.PMID:36336528 | DOI:10.1016/j.vaccine.2022.10.064
Source: Vaccine - November 6, 2022 Category: Allergy & Immunology Authors: Thomas Ricks Mallory J Trent C Raina MacIntyre Source Type: research

High-dose influenza vaccines for the prevention of hospitalization due to cardiovascular events in older adults in the nursing home: Post-hoc analysis of a cluster-randomized trial
Vaccine. 2022 Oct 13:S0264-410X(22)01215-4. doi: 10.1016/j.vaccine.2022.09.085. Online ahead of print.ABSTRACTOlder adults are at high risk of major acute cardiovascular events (MACE) linked to influenza illness andpreventable by influenza vaccination. It is unknown whether high-dose vaccine might incrementally reduce the risk of MACE.We conducted a post-hoc analysis of data collected from a pragmatic cluster randomized study of 823 nursing homes (NH) randomized to standard-dose (SD) or high-dose (HD) influenza vaccine in the 2013-14 season. Adults age 65 year or older who are Medicare-enrolled long-stay residents were inc...
Source: Vaccine - October 16, 2022 Category: Allergy & Immunology Authors: Elie A Saade Yasin Abul Kevin McConeghy H Edward Davidson Lisa Han Nina Joyce David H Canaday Leon Hsueh Elliott Bosco Stefan Gravenstein Source Type: research

Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study
CONCLUSION: This study shows acceptable safety profiles of COVID-19 vaccines among recipients of BNT162b2, CoronaVac, and ChAdOx1 vaccines. This information can be used together with effectiveness data for risk-benefit analysis of the vaccination program. Further surveillance with more data is required to assess AESIs following COVID-19 vaccination in short- and long-term.PMID:35667917 | PMC:PMC9163997 | DOI:10.1016/j.vaccine.2022.05.075
Source: Vaccine - June 6, 2022 Category: Allergy & Immunology Authors: Norazida Ab Rahman Ming Tsuey Lim Fei Yee Lee Sing Chet Lee Azuana Ramli Siti Nurhafizah Saharudin Teck Long King Emelyne Bani Anak Jam Nor Aliya Ayub Raj Kumar Sevalingam Rashidah Bahari Nor Nadziroh Ibrahim Fatihah Mahmud Sheamini Sivasampu Kalaiarasu M Source Type: research

Effectiveness of the influenza vaccine at reducing adverse events in patients with heart failure: A systematic review and meta-analysis
CONCLUSIONS: Influenza vaccination appears to reduce adverse cardiovascular events, although the certainty of the evidence is low or very low. Rigorous randomized controlled trial evidence is needed to further examine the protective effect of the influenza vaccine in heart failure patients.PMID:35562195 | DOI:10.1016/j.vaccine.2022.04.039
Source: Vaccine - May 13, 2022 Category: Allergy & Immunology Authors: Christopher Gupta Anjali Sachdeva Jigish Khamar Cecilia Bu Jessica Bartoszko Mark Loeb Source Type: research

Changes in incidence rates of outcomes of interest in vaccine safety studies during the COVID-19 pandemic
CONCLUSION: Rates of some clinical outcomes during the pandemic changed and should not be used as historical background rates in vaccine safety studies. Inclusion of telehealth visits should be considered for vaccine studies involving Bell's palsy, ITP, and narcolepsy/cataplexy.PMID:35465977 | DOI:10.1016/j.vaccine.2022.04.037
Source: Vaccine - April 25, 2022 Category: Allergy & Immunology Authors: Stanley Xu Vennis Hong Lina S Sy Sungching C Glenn Denison S Ryan Kerresa L Morrissette Jennifer C Nelson Simon J Hambidge Bradley Crane Ousseny Zerbo Malini B DeSilva Jason M Glanz James G Donahue Elizabeth Liles Jonathan Duffy Lei Qian Source Type: research

Assessment of pre-specified adverse events following varicella vaccine: A population-based self-controlled risk interval study.
CONCLUSIONS: We detected a small risk of incidental pneumonia associated with varicella vaccine in the 6th week after immunization. There was no increase in the risk of other pre-specified adverse events. PMID: 32046891 [PubMed - as supplied by publisher]
Source: Vaccine - February 7, 2020 Category: Allergy & Immunology Authors: Liu CH, Yeh YC, Huang WT, Chie WC, Chan KA Tags: Vaccine Source Type: research